Literature DB >> 17410534

Comparison of gene expression data from human and mouse breast cancers: identification of a conserved breast tumor gene set.

Andreas Klein1, Ralf Wessel, Monika Graessmann, Martin Jürgens, Iver Petersen, Rita Schmutzler, Dieter Niederacher, Norbert Arnold, Alfons Meindl, Siegfried Scherneck, Susanne Seitz, Adolf Graessmann.   

Abstract

The aim of our work was to establish a database for breast cancer gene expression data in order to compare human and mouse breast cancer. We identified human and mouse homologues genes and compared the expression profile of 24 human breast tumors with 6 WAP-SVT/t breast tumors (WAP-SVT/t animals, line 8). Our studies confirmed the heterogeneity in gene expression of human as well as mouse breast cancer cells. However, 63 genes were found to be differentially expressed (upregulated: 40; downregulated: 23 genes) in at least 75% of the breast tumors of both species. To differentiate between early and late events in tumor formation, we compared the 63 differentially expressed genes with a mouse data set obtained from hyperplastic mammary glands. This revealed that the majority of the early deregulated genes are cell proliferation specific. These early changes seem to be necessary although not sufficient for breast cancer formation. Late alterations concern mainly genes belonging to the category of cell communication and metabolism. Interestingly, most of the 63 conserved genes are commonly associated with tumorigenesis. Copyright (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2007        PMID: 17410534     DOI: 10.1002/ijc.22630

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  17 in total

1.  A pathway-based classification of human breast cancer.

Authors:  Michael L Gatza; Joseph E Lucas; William T Barry; Jong Wook Kim; Quanli Wang; Matthew D Crawford; Michael B Datto; Michael Kelley; Bernard Mathey-Prevot; Anil Potti; Joseph R Nevins
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-24       Impact factor: 11.205

2.  From aneuploidy to cancer: the evolution of a new species?

Authors:  Samuel Knauss; Andreas Klein
Journal:  J Biosci       Date:  2012-06       Impact factor: 1.826

3.  The therapeutic response of ER+/HER2- breast cancers differs according to the molecular Basal or Luminal subtype.

Authors:  François Bertucci; Pascal Finetti; Anthony Goncalves; Daniel Birnbaum
Journal:  NPJ Breast Cancer       Date:  2020-03-06

4.  KPNA2 protein expression in invasive breast carcinoma and matched peritumoral ductal carcinoma in situ.

Authors:  Anja Dankof; Florian R Fritzsche; Edgar Dahl; Stefan Pahl; Peter Wild; Manfred Dietel; Arndt Hartmann; Glen Kristiansen
Journal:  Virchows Arch       Date:  2007-09-27       Impact factor: 4.064

5.  SNP microarray analyses reveal copy number alterations and progressive genome reorganization during tumor development in SVT/t driven mice breast cancer.

Authors:  Christoph Standfuss; Heike Pospisil; Andreas Klein
Journal:  BMC Cancer       Date:  2012-08-31       Impact factor: 4.430

6.  Identification of early molecular markers for breast cancer.

Authors:  Céline Kretschmer; Anja Sterner-Kock; Friederike Siedentopf; Winfried Schoenegg; Peter M Schlag; Wolfgang Kemmner
Journal:  Mol Cancer       Date:  2011-02-11       Impact factor: 27.401

7.  EphB6 receptor modulates micro RNA profile of breast carcinoma cells.

Authors:  Lokesh Bhushan; Raj P Kandpal
Journal:  PLoS One       Date:  2011-07-19       Impact factor: 3.240

8.  A genomic analysis of mouse models of breast cancer reveals molecular features of mouse models and relationships to human breast cancer.

Authors:  Daniel P Hollern; Eran R Andrechek
Journal:  Breast Cancer Res       Date:  2014-06-05       Impact factor: 6.466

9.  Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization.

Authors:  Renaud Sabatier; Pascal Finetti; Arnaud Guille; José Adelaide; Max Chaffanet; Patrice Viens; Daniel Birnbaum; François Bertucci
Journal:  Mol Cancer       Date:  2014-10-02       Impact factor: 27.401

10.  Tamoxifen therapy benefit predictive signature coupled with prognostic signature of post-operative recurrent risk for early stage ER+ breast cancer.

Authors:  Hao Cai; Xiangyu Li; Jing Li; Lu Ao; Haidan Yan; Mengsha Tong; Qingzhou Guan; Mengyao Li; Zheng Guo
Journal:  Oncotarget       Date:  2015-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.